GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (OTCPK:MYPHY) » Definitions » Sale Of Investment

Mayne Pharma Group (Mayne Pharma Group) Sale Of Investment : $61.33 Mil (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Mayne Pharma Group Sale Of Investment?

Mayne Pharma Group's sale of investment for the six months ended in Dec. 2023 was $61.33 Mil. It means Mayne Pharma Group gained $61.33 Mil from selling investments. Mayne Pharma Group's sale of investment for the trailing twelve months (TTM) ended in Dec. 2023 was $61.33 Mil.

Compared with last quarter ($0.00 Mil in Jun. 2023 ), Mayne Pharma Group gained more money from selling investments in Dec. 2023 ($61.33 Mil).

Mayne Pharma Group Sale Of Investment Historical Data

The historical data trend for Mayne Pharma Group's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mayne Pharma Group Sale Of Investment Chart

Mayne Pharma Group Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mayne Pharma Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 61.33

Mayne Pharma Group Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $61.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mayne Pharma Group Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Mayne Pharma Group (Mayne Pharma Group) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (OTCPK:MYPHY) » Definitions » Sale Of Investment
Comparable Companies
ASX:FRE LLY JNJ MRK ABBV LSE:AZN XSWX:NOVN XSWX:ROG AMGN PFE XPAR:SAN BMY LSE:GSK GILD TSE:4568 TSE:4519 SHSE:600276 BIIB XTER:BAYN TSE:4578
Traded in Other Exchanges
MAYNF:USA HG6:Germany MYX:Australia
Address
1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Website
http://www.maynepharma.com
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women's health products in the US. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.